SK&A broadens database coverage

Healthcare research firm SK&A has added new information and target data to its office-based physicians database, allowing clients a more precise understanding of a given practice.

The independently audited database maintains information on more than 638,340 US physicians, and will now provide secondary data such as whether or not a given practice accepts Medicare and Medicaid, for example. Additionally, the database will now provide information such as the number of exam rooms and office hours of each practice, whether a practice is accepting new patients and using electronic medical records, and what primary and secondary languages are used.

“The…insights gained from the response to these new survey questions will enable more sophisticated analysis and targeting of every physician and physician office in the US,” said Dave Escalante, president and CEO at SK&A, in a statement.

SK&A's database already includes physician information such as contact information, NPI, DEA and UPIN numbers, prescribing volume, participation in clinical trials and availability to see sales reps.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.